ExploreWatchlistsPricing
  1. JP-listed companies
  2. Immuno-Biological Laboratories Co., Ltd.
  3. Financials
  4. Net income

Immuno-Biological Laboratories Co., Ltd. (4570)

Market cap
¥14.1B
P/E ratio
53.1x
Develops antibody-based diagnostic tools and testing services for medical research, plus manufactures cosmetics using human-type collagen from silkworms.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndNet income (Million JPY)YoY (%)
Mar 31, 2025249+33.40%
Mar 31, 2024187-164.44%
Mar 31, 2023-290+11.97%
Mar 31, 2022-259-18.84%
Mar 31, 2021-319-52.28%
Mar 31, 2020-668+299.31%
Mar 31, 2019-167+217.87%
Mar 31, 2018-53-97.49%
Mar 31, 2017-2,094+6466.14%
Mar 31, 2016-32-79.87%
Mar 31, 2015-158+25.25%
Mar 31, 2014-127-182.66%
Mar 31, 2013153+257.42%
Mar 31, 201243

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat